DrugPatentWatch Database Preview
Patent: 8,551,980
Summary for Patent: 8,551,980
Title: | Substituted triazolopyridines |
Abstract: | The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: Formula (I), in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis proliferative of diseases, as well as to intermediate compounds useful in the preparation of said compounds. ##STR00001## |
Inventor(s): | Schulze; Volker (Bergfelde, DE), Koppitz; Marcus (Berlin, DE), Kosemund; Dirk (Berlin, DE), Bader; Benjamin (Berlin, DE), Lienau; Philip (Berlin, DE), Briem; Hans (Berlin, DE), Holton; Simon (Berlin, DE), Siemeister; Gerhard (Berlin, DE), Prechtl; Stefan (Berlin, DE), Wengner; Antje Margret (Berlin, DE) |
Assignee: | Bayer Intellectual Property GmbH (Monheim, DE) |
Application Number: | 13/512,737 |
Patent Claims: | see list of patent claims |
Details for Patent 8,551,980
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | Bayer Intellectual Property GmbH (Monheim, DE) | 2029-11-30 | RX | Orphan | search |
Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Bayer Intellectual Property GmbH (Monheim, DE) | 2029-11-30 | RX | Orphan | search |
Genentech | RITUXAN | rituximab | VIAL | 103705 | 001 | 1997-11-26 | Start Trial | Bayer Intellectual Property GmbH (Monheim, DE) | 2029-11-30 | RX | search | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,551,980
Country | Patent Number | Publication Date |
---|---|---|
World Intellectual Property Organization (WIPO) | 2011063907 | Jun 03, 2011 |
United States of America | 2012328611 | Dec 27, 2012 |
Japan | 2013512263 | Apr 11, 2013 |
Japan | 5805652 | Nov 04, 2015 |
Hong Kong | 1180333 | Mar 24, 2017 |
>Country | >Patent Number | >Publication Date |